Across TCGA pan-cancer cohorts, GLDN Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GLDN data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher GLDN Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GLDN expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

LGG, PRAD, and STAD are the cancer types where GLDN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	DFS	Median	All	0.068	0.833	<.001	6	view →
PRAD	DFS	Median	All	0.626	0.936	<.001	6	view →
STAD	DFS	Median	II,III,IV	1.000	0.630	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: GLDN tumor-vs-normal RNA expression · all GLDN data types